Skip To Main Content
Charlotte Warren on Muck Rack

Charlotte Warren

Hallowell
As seen in: Nature, Yahoo News, GlobeNewswire, The Lancet, Bangor Daily News, EcoWatch, StreetInsider, ADVFN, The State Journal-Register, The Sun Chronicle and

Get in touch with Charlotte

Contact Charlotte, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Articles

Faecal mtDNA heteroplasmy as a non-invasive biomarker in m.3243 A > G mitochondrial disease

|
By Charlotte Warren, Renae Stefanetti, Isabel Barrow, David Houghton, Robert E. McFarland, Helen A. L. Tuppen, Yi Shiau Ng, Alasdair Blain, Grainne Gorman, Gráinne S. Gorman, Nell Richardson
| Nature Verified
Abstract Quantifying mitochondrial DNA (mtDNA) heteroplasmy is critical for diagnosis, prognosis, and monitoring of mitochondrial disease, particularly that caused by the m.3243 A > G pathogenic variant, where tissue-specific heteroplasmy contributes to disease expression. However, current methods often rely on invasive or clinic-based sampling, limiting accessibility and repeat testing.
Open in Who Shared Issue with article?

Mavodelpar in patients with primary mitochondrial myopathy: a phase 1 trial

|
By Renae Stefanetti, Chiara Pizzamiglio, Alasdair Blain, Lisa Alcock, Gavin Hudson, Jane Newman, Naomi Thomas, Charlotte Warren, Philip Brown, David Houghton, Heather Hunter, Albert Lim, Yi Shiau Ng, Catherine L. Feeney, Louise Germain, Enrico Bugiardini, Michael Hanna, Robert E. McFarland, Grainne Gorman, Gráinne S. Gorman, Huizhong Su, Helen A. L. Tuppen, Iwona Skorupinska, Robert D. S. Pitceathly
| Nature Verified
Abstract Primary mitochondrial myopathies (PMM) are rare, genetically-defined disorders characterised by defects of oxidative phosphorylation, predominantly affecting skeletal muscle. This Phase 1b open-label trial evaluated mavodelpar, a selective peroxisome proliferator-activated receptor delta (PPARδ) agonist, over 12 weeks (Part A), with an optional 36 week extension (Part B) in adults with PMM.
Open in Who Shared Issue with article?

Suffolk Inks Enterprise Agreement with Trunk Tools, Cementing AI Partnership

|
By Charlotte Warren
| The Sun Chronicle Verified
Boston, MA, March 04, 2026 (GLOBE NEWSWIRE) -- Suffolk, one of the most innovative construction enterprises in the country, has selected Trunk Tools as an enterprise AI partner — deploying the platform and agents across more than 1,500+ field users nationwide. For both companies, this agreement is less a starting line than a milestone: the result of a relationship years in the making, and a shared conviction that AI belongs at the center of how leading contractors operate.
Open in Who Shared View Duplicates (101) Issue with article?
See all 26 licensed articles (27 Total)